Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Menon V, Ayala VI, Rangaswamy SP, Kalisz I, Whitney S, Galmin L, Ashraf A, LaBranche C, Montefiori D, Petrovsky N, Kalyanaraman VS, Pal R.

J Gen Virol. 2017 Aug;98(8):2143-2155. doi: 10.1099/jgv.0.000863. Epub 2017 Jul 31.

2.

Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge.

Tuero I, Mohanram V, Musich T, Miller L, Vargas-Inchaustegui DA, Demberg T, Venzon D, Kalisz I, Kalyanaraman VS, Pal R, Ferrari MG, LaBranche C, Montefiori DC, Rao M, Vaccari M, Franchini G, Barnett SW, Robert-Guroff M.

PLoS Pathog. 2015 Aug 12;11(8):e1005101. doi: 10.1371/journal.ppat.1005101. eCollection 2015 Aug.

3.

Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques.

Menon V, Priya RS, Labranche C, Montefiori D, Mahalingam S, Kalyanaraman VS, Pal R.

J Med Primatol. 2015 Oct;44(5):275-85. doi: 10.1111/jmp.12178. Epub 2015 Jun 15.

PMID:
26075700
4.

Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.

Sneha Priya R, Veena M, Kalisz I, Whitney S, Priyanka D, LaBranche CC, Sri Teja M, Montefiori DC, Pal R, Mahalingam S, Kalyanaraman VS.

J Biol Chem. 2015 Apr 3;290(14):9195-208. doi: 10.1074/jbc.M114.621185. Epub 2015 Feb 17.

5.

Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.

Demberg T, Brocca-Cofano E, Kuate S, Aladi S, Vargas-Inchaustegui DA, Venzon D, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, DiPasquale J, Ruprecht RM, Montefiori DC, Srivastava I, Barnett SW, Robert-Guroff M.

Virology. 2013 Jun 5;440(2):210-21. doi: 10.1016/j.virol.2013.02.024. Epub 2013 Mar 22.

6.

Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques.

Demberg T, Brocca-Cofano E, Xiao P, Venzon D, Vargas-Inchaustegui D, Lee EM, Kalisz I, Kalyanaraman VS, Dipasquale J, McKinnon K, Robert-Guroff M.

J Virol. 2012 Dec;86(23):12591-604. doi: 10.1128/JVI.00298-12. Epub 2012 Sep 12.

7.

Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.

Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, Kalisz I, Kalyanaraman VS, Pal R, Montefiori D, Keele BF, Robert-Guroff M.

J Virol. 2012 Apr;86(8):4644-57. doi: 10.1128/JVI.06812-11. Epub 2012 Feb 15.

8.

Mechanism of host cell MAPK/ERK-2 incorporation into lentivirus particles: characterization of the interaction between MAPK/ERK-2 and proline-rich-domain containing capsid region of structural protein Gag.

Gupta P, Singhal PK, Rajendrakumar P, Padwad Y, Tendulkar AV, Kalyanaraman VS, Schmidt RE, Srinivasan A, Mahalingam S.

J Mol Biol. 2011 Jul 22;410(4):681-97. doi: 10.1016/j.jmb.2011.03.022.

PMID:
21762808
9.

Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.

Patterson LJ, Daltabuit-Test M, Xiao P, Zhao J, Hu W, Wille-Reece U, Brocca-Cofano E, Kalyanaraman VS, Kalisz I, Whitney S, Lee EM, Pal R, Montefiori DC, Dandekar S, Seder R, Roederer M, Wiseman RW, Hirsch V, Robert-Guroff M.

Virology. 2011 Mar 1;411(1):87-102. doi: 10.1016/j.virol.2010.12.033. Epub 2011 Jan 14.

10.

Unsung hero Robert C. Gallo.

Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D.

Science. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. No abstract available.

PMID:
19131607
11.

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M.

J Virol. 2009 Jan;83(2):791-801. doi: 10.1128/JVI.01672-08. Epub 2008 Oct 29.

12.

Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.

Demberg T, Boyer JD, Malkevich N, Patterson LJ, Venzon D, Summers EL, Kalisz I, Kalyanaraman VS, Lee EM, Weiner DB, Robert-Guroff M.

J Virol. 2008 Nov;82(21):10911-21. doi: 10.1128/JVI.01129-08. Epub 2008 Aug 27.

13.

A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopes.

Srinivasan A, Ayyavoo V, Mahalingam S, Kannan A, Boyd A, Datta D, Kalyanaraman VS, Cristillo A, Collman RG, Morellet N, Sawaya BE, Murali R.

Virol J. 2008 Aug 23;5:99. doi: 10.1186/1743-422X-5-99.

14.

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, Larsen K, Flanary L, Kalyanaraman VS, Pal R, Titti F, Patterson LJ, Heath MJ, O'Connor DH, Cafaro A, Ensoli B, Robert-Guroff M.

Vaccine. 2008 Jun 19;26(26):3312-21. doi: 10.1016/j.vaccine.2008.03.100. Epub 2008 Apr 30.

15.

Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.

Patterson LJ, Beal J, Demberg T, Florese RH, Malkevich N, Venzon D, Aldrich K, Richardson E, Kalyanaraman VS, Kalisz I, Lee EM, Montefiori DC, Robey FA, Robert-Guroff M.

Virology. 2008 May 10;374(2):322-37. doi: 10.1016/j.virol.2007.12.037. Epub 2008 Feb 5.

16.

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

Zhou Q, Hidajat R, Peng B, Venzon D, Aldrich MK, Richardson E, Lee EM, Kalyanaraman VS, Grimes G, Gómez-Román VR, Summers LE, Malkevich N, Robert-Guroff M.

Vaccine. 2007 Nov 19;25(47):8021-35. Epub 2007 Sep 29.

PMID:
17935840
17.

HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.

Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S, Restrepo S, Suschak J, Ferrari MG, Chung HK, Kalyanaraman VS, Markham P, Pal R.

Virology. 2007 Sep 15;366(1):197-211. Epub 2007 May 11.

18.

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, Ensoli B, Robert-Guroff M.

J Virol. 2007 Apr;81(7):3414-27. Epub 2007 Jan 17.

19.

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M.

J Immunol. 2006 Sep 15;177(6):4028-36.

20.

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

Gómez-Román VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS, Venzon D, Srivastava I, Barnett SW, Robert-Guroff M.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7.

PMID:
16940858
21.

Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity.

Lamalle-Bernard D, Munier S, Compagnon C, Charles MH, Kalyanaraman VS, Delair T, Verrier B, Ataman-Onal Y.

J Control Release. 2006 Sep 28;115(1):57-67. Epub 2006 Jul 13.

PMID:
16919350
22.

Subunit recombinant vaccine protects against monkeypox.

Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G.

J Immunol. 2006 Aug 15;177(4):2552-64.

23.

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.

Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH, Kalyanaraman VS, Pal R, Lee EM, Zhao J, Cristillo A, Robert-Guroff M.

Virology. 2006 Sep 15;353(1):83-98. Epub 2006 Jun 30.

24.

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S.

Virology. 2006 Jun 20;350(1):34-47. Epub 2006 Apr 17.

25.

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.

Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G.

J Virol. 2006 Apr;80(8):3732-42.

26.

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.

Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S.

Virology. 2006 May 10;348(2):341-53.

27.

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.

Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R.

Virology. 2006 Mar 1;346(1):151-68. Epub 2005 Dec 2.

28.

Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits.

Pal R, Yu Q, Wang S, Kalyanaraman VS, Nair BC, Hudacik L, Whitney S, Keen T, Hung CL, Hocker L, Kennedy JS, Markham P, Lu S.

Vaccine. 2006 Feb 20;24(8):1225-34. Epub 2005 Oct 10.

PMID:
16219399
29.

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.

Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, Kalyanaraman VS, Gallo RC, Racz P.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14807-12. Epub 2005 Sep 30.

30.

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.

Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P.

J Med Primatol. 2005 Oct;34(5-6):226-36.

31.

Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.

Zhao J, Voltan R, Peng B, Davis-Warren A, Kalyanaraman VS, Alvord WG, Aldrich K, Bernasconi D, Buttò S, Cafaro A, Ensoli B, Robert-Guroff M.

Virology. 2005 Nov 10;342(1):1-12. Epub 2005 Aug 18.

32.

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.

Peng B, Wang LR, Gómez-Román VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M.

J Virol. 2005 Aug;79(16):10200-9.

33.

Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques.

Malkevitch N, Rohne D, Pinczewski J, Aldrich K, Kalyanaraman VS, Letvin NL, Robert-Guroff M.

AIDS Res Hum Retroviruses. 2004 Feb;20(2):235-44.

PMID:
15018712
34.

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M.

J Virol. 2004 Mar;78(5):2212-21.

35.

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.

Zhao J, Lou Y, Pinczewski J, Malkevitch N, Aldrich K, Kalyanaraman VS, Venzon D, Peng B, Patterson LJ, Edghill-Smith Y, Woodward R, Pavlakis GN, Robert-Guroff M.

Vaccine. 2003 Sep 8;21(25-26):4022-35.

PMID:
12922139
36.

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalyanaraman VS, Pavlakis GN, Robert-Guroff M.

J Virol. 2003 Aug;77(16):8607-20.

37.

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Zhao J, Pinczewski J, Gómez-Román VR, Venzon D, Kalyanaraman VS, Markham PD, Aldrich K, Moake M, Montefiori DC, Lou Y, Pavlakis GN, Robert-Guroff M.

J Virol. 2003 Aug;77(15):8354-65.

38.

The lectin jacalin induces phosphorylation of ERK and JNK in CD4+ T cells.

Tamma SM, Kalyanaraman VS, Pahwa S, Dominguez P, Modesto RR.

J Leukoc Biol. 2003 May;73(5):682-8.

PMID:
12714584
39.

Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques.

Edghill-Smith YY, Aldrich K, Zhao J, Pinczewski J, Kalyanaraman VS, Johnson M, Heyliger A, Perrin RP, Woodward R, Robert-Guroff M.

J Med Primatol. 2002 Dec;31(6):313-22.

PMID:
12519209
40.

Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.

Hel Z, Tryniszewska E, Tsai WP, Johnson JM, Harrod R, Fullen J, Kalyanaraman VS, Altman JD, McNally J, Karpova T, Felber BK, Tartaglia J, Franchini G.

DNA Cell Biol. 2002 Sep;21(9):619-26.

PMID:
12396604
41.

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, DeVico A, Pal R.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7. Epub 2002 Aug 21.

42.

A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Agwale SM, Shata MT, Reitz MS Jr, Kalyanaraman VS, Gallo RC, Popovic M, Hone DM.

Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10037-41. Epub 2002 Jul 2.

43.

Intravirion display of a peptide corresponding to the dimer structure of protease attenuates HIV-1 replication.

Cartas M, Singh SP, Serio D, Rizvi TA, Kalyanaraman VS, Goldsmith CS, Zaki SR, Weber IT, Srinivasan A.

DNA Cell Biol. 2001 Dec;20(12):797-805.

PMID:
11879573
44.

Virion-associated HIV-1 Vpr: variable amount in virus particles derived from cells upon virus infection or proviral DNA transfection.

Singh SP, Tungaturthi P, Cartas M, Tomkowicz B, Rizvi TA, Khan SA, Kalyanaraman VS, Srinivasan A.

Virology. 2001 Apr 25;283(1):78-83.

45.

Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Singh SP, Tomkowicz B, Lai D, Cartas M, Mahalingam S, Kalyanaraman VS, Murali R, Srinivasan A.

J Virol. 2000 Nov;74(22):10650-7.

46.

Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells.

Lai D, Singh SP, Cartas M, Murali R, Kalyanaraman VS, Srinivasan A.

FEBS Lett. 2000 Mar 10;469(2-3):191-5.

47.
48.

Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.

Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M.

AIDS. 2000 Nov 10;14(16):2445-55.

PMID:
11101054
49.

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Buge SL, Murty L, Arora K, Kalyanaraman VS, Markham PD, Richardson ES, Aldrich K, Patterson LJ, Miller CJ, Cheng SM, Robert-Guroff M.

J Virol. 1999 Sep;73(9):7430-40.

50.

HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Srivastava M, Cartas M, Rizvi TA, Singh SP, Serio D, Kalyanaraman VS, Pollard HB, Srinivasan A.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2704-9.

Supplemental Content

Loading ...
Support Center